Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Solid Tumors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44400   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,524 result(s) found for: Solid Tumors. Displaying page 3 of 77.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-003708-33 Sponsor Protocol Number: ML43332 Start Date*: 2023-03-15
    Sponsor Name:Roche Farma S.A.U.
    Full Title: A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE COHORTS STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RE...
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001394-16 Sponsor Protocol Number: GCT1029-01 Start Date*: 2018-03-29
    Sponsor Name:Genmab B.V.
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors
    Medical condition: Malignant solid tumors: Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001509-33 Sponsor Protocol Number: B9991025 Start Date*: 2018-05-31
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH ...
    Medical condition: Locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hormone receptor-positive (HR+) / human epide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065147 Malignant solid tumor LLT
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DK (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-000509-29 Sponsor Protocol Number: GCT1042-02 Start Date*: 2022-11-04
    Sponsor Name:Genmab A/S
    Full Title: A Phase 1/2, Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
    Medical condition: Metastatic Solid Malignant tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001923-11 Sponsor Protocol Number: 18-BI-1206-03 Start Date*: 2019-12-09
    Sponsor Name:BioInvent International AB
    Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL...
    Medical condition: Advanced solid tumors who have relapsed or are refractory to anti-PD1 or anti-PDL1 therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003998-26 Sponsor Protocol Number: GCT1044-01 Start Date*: 2020-05-16
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumors
    Medical condition: Malignant Solid Tumors, per protocol GCT1044-01
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003602-16 Sponsor Protocol Number: PM1183-A-014-15 Start Date*: 2022-02-24
    Sponsor Name:Pharma Mar S.A.
    Full Title: Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors.
    Medical condition: Selected Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001141-41 Sponsor Protocol Number: 08-C-0007 Start Date*: 2012-09-18
    Sponsor Name:National Cancer Institute NCI
    Full Title: A PHASE I STUDY OF IPILIMUMAB (ANTI-CTLA-4) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH TREATMENT REFRACTORY CANCER
    Medical condition: Sarcoma - Wilm's Tumor - Lymphoma - Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005604-35 Sponsor Protocol Number: APEC1621B Start Date*: 2022-01-18
    Sponsor Name:National Cancer Institute (NCI)
    Full Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
    Medical condition: Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-003385-84 Sponsor Protocol Number: GO40782(RXDX-101-02) Start Date*: 2016-03-15
    Sponsor Name:F. Hoffman-La Roche Ltf
    Full Title: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRA...
    Medical condition: Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000368-17 Sponsor Protocol Number: CTKI258A2X01B Start Date*: 2014-05-26
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: An open label, multi-center, extension study to evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who continue to receive treatment with dovitinib (TKI258) in N...
    Medical condition: Patients with solid tumours
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) DK (Completed) NL (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004685-25 Sponsor Protocol Number: GO29665 Start Date*: 2016-10-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020962 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) IE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019121-34 Sponsor Protocol Number: E-3810-I-01 Start Date*: 2011-03-28
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics, and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase ...
    Medical condition: Dose escalation: solid tumors failing standard therapy. Dose-expansion: solid tumors A) with FGFR1 amplification and for breast cancer ? 1 prior endocrine therapy if ER+ or ? 1 chemotherapy otherwi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000690-23 Sponsor Protocol Number: ADVL0612;NCI-07-C-0220 Start Date*: 2012-02-29
    Sponsor Name:National Institution of Health (NCI)
    Full Title: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors
    Medical condition: Paediatric solid tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023062-40 Sponsor Protocol Number: PRP-001 Start Date*: 2011-04-19
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib (BMN 673) in Patients with Advanced or Recurrent Solid Tumors
    Medical condition: Advanced or recurrent solid tumors for which there is no accepted standard treatment or for which standard treatment has failed. Patients may also be eligible if they are unable or decline to unde...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001224-36 Sponsor Protocol Number: A4021010 Start Date*: 2005-06-10
    Sponsor Name:Pfizer Inc. - Research & Development
    Full Title: Phase 1, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-751,871 in Patients with Advanced Solid Tumours
    Medical condition: Advanced Solid Tumours
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002980-81 Sponsor Protocol Number: CO-3810-101 Start Date*: 2021-02-10
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor
    Medical condition: Advanced gynecological solid tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003564-24 Sponsor Protocol Number: JAB-3312-1003 Start Date*: 2023-05-05
    Sponsor Name:Jacobio Pharmaceuticals Co., Ltd.
    Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P...
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004569-37 Sponsor Protocol Number: ANV419-001 Start Date*: 2021-05-23
    Sponsor Name:Anaveon AG
    Full Title: ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors
    Medical condition: Relapsed/refractory advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003118-42 Sponsor Protocol Number: D419EC00001 Start Date*: 2019-04-16
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patien...
    Medical condition: Advanced Solid Tumors and Hematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 24 03:01:01 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA